Revolutionizing Treatment in the Battle Against Blood Cancer

• Post author:andrewkaretas
• Post published:April 28, 2021
• Post category:Perspectives

Continue ReadingRevolutionizing Treatment in the Battle Against Blood Cancer

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

• Post author:andrewkaretas
• Post published:April 28, 2021
• Post category:Latest News

Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

Continue ReadingAllogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology

PD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs

• Post author:andrewkaretas
• Post published:April 18, 2021
• Post category:PLATFORM/Scientific Publications

Continue ReadingPD1 TurboCAR™ T Cells: PD1-Resistant CAR T Cells With Programmable Cytokine Signaling Outputs

Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

• Post author:andrewkaretas
• Post published:December 22, 2020
• Post category:BCMA/Scientific Publications

Continue ReadingPreclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T™ Cell Therapy for the Treatment of Multiple Myeloma

Investigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

• Post author:andrewkaretas
• Post published:December 18, 2020
• Post category:CD70/Scientific Publications

Continue ReadingInvestigation of ALLO-316: A Fratricide-Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML

First-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

• Post author:andrewkaretas
• Post published:December 9, 2020
• Post category:BCMA/Scientific Publications

Continue ReadingFirst-in-Human Study of the Allogeneic Anti-BCMA ALLO-715 CAR T cell Therapy and the Anti-CD52 Mab ALLO-647 in Relapsed/Refractory Multiple Myeloma (UNIVERSAL Study)

Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

• Post author:andrewkaretas
• Post published:October 18, 2020
• Post category:FLT3/Scientific Publications

Continue ReadingAllogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery

American Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs

• Post author:andrewkaretas
• Post published:June 18, 2020
• Post category:PLATFORM/Scientific Publications

Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – SMIC CAR T Cells: CAR T with Temporally-Controlled, Programmable Cytokine Signaling Outputs

American Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer

• Post author:andrewkaretas
• Post published:June 18, 2020
• Post category:DLL3/Scientific Publications

Continue ReadingAmerican Association for Cancer Research (AACR) June 2020 – Screening and Characterization of AlloCAR T™ Targeting DLL3 for the Treatment of Small Cell Lung Cancer

Positive Progress in AlloCAR T™:The Revolution in Cell Therapy is on the Horizon

• Post author:andrewkaretas
• Post published:May 29, 2020
• Post category:Perspectives

Continue ReadingPositive Progress in AlloCAR T™:The Revolution in Cell Therapy is on the Horizon